Unitary patent opt-out misery; Delaware filing trends; first German life sciences AASI; Amgen v Sanofi ruling; USPTO fee hike; plus much more

Unitary patent opt-out misery; Delaware filing trends; first German life sciences AASI; Amgen v Sanofi ruling; USPTO fee hike; plus much more

Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week.

MONDAY 15 May

UPC system experiencing severe problems as patentees race to opt out their rights. Read more here

IAM-Docket Navigator report: Patent holders flee Delaware as disclosure orders continue to bite. Read more here     

TUESDAY 16 May

SCOTUS turns down much-watched ‘skinny label’ appeal in blow to generic drug companies. Read more here

US PTAB ruling shakes ground of VLSI’s $2.18 billion patent verdict. Read more here

WEDNESDAY 17 May

Long read: Efficient IP management in a market increasingly using open source. Read more here

A briefing on the US IP enforcement coordinator as Deborah Robinson nominated for post. Read more here

THURSDAY 18 May

Weekly column: The BlackBerry patent sale is a missed opportunity for company and country. Read more here

German court issues first ever AASI in life sciences case. Read more here

Timeline of allegations against Federal Circuit Judge Pauline Newman. Read more here

FRIDAY 19 May

UPC central division will have branch in Milan, Italian government announces. Read more here

Patent holders critical of some proposed USPTO fee hikes geared to changing filing behaviour. Read more here

Five key takeaways from SCOTUS’ landmark Amgen v Sanofi enablement ruling. Read more here

SATURDAY 20 May

Opinion: USPTO’s new Catch-22 targets Unified Patents in standing requirement reforms. Read more here

Unlock unlimited access to all IAM content